Tag Archives: myositis

Introduction Immune checkpoint inhibitors (ICI) are a class of novel anticancer therapies with significant improvement in outcomes.1 They work by stimulating immune-mediated recognition and clearance of cancer cells. This may lead to immune cell over-activation manifesting as inflammatory toxicities.1,2 While ICI-induced toxicities, like colitis, endocrinopathies and dermatitis, may occur in up to 40% of people, myocarditis is rare, occurring in less than 1% of the treated population. Furthermore, an overlap syndrome of myocarditis, myositis, and myasthenia is extremely uncommon, and only a few cases have been reported so far.3 This overlap s

No content available